{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:18:09Z","timestamp":1791919089683,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program","doi-asserted-by":"crossref","award":["2011CB510002"],"award-info":[{"award-number":["2011CB510002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program","doi-asserted-by":"crossref","award":["2012CB944601"],"award-info":[{"award-number":["2012CB944601"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program","doi-asserted-by":"crossref","award":["2012CB517902"],"award-info":[{"award-number":["2012CB517902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471156"],"award-info":[{"award-number":["81471156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81271260"],"award-info":[{"award-number":["81271260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Funds","award":["14JJ1008"],"award-info":[{"award-number":["14JJ1008"]}]},{"name":"Clinical Research Funds","award":["2014L03"],"award-info":[{"award-number":["2014L03"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.parkreldis.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T16:30:18Z","timestamp":1457800218000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Safety and efficacy of valproic acid treatment in SCA3\/MJD patients"],"prefix":"10.1016","volume":"26","author":[{"given":"Li-Fang","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Maw","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Sha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.03.005_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/gim.2013.28","article-title":"Hereditary ataxias: overview","volume":"15","author":"Jayadev","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archneur.57.4.540","article-title":"Frequency of SCA1, SCA2, SCA3\/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds","volume":"57","author":"Tang","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(04)00737-9","article-title":"Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis","volume":"3","author":"Schols","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410390411","article-title":"Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features","volume":"39","author":"Durr","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awp292","article-title":"Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3","volume":"133","author":"Menzies","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tins.2009.06.002","article-title":"Multiple roles of HDAC inhibition in neurodegenerative conditions","volume":"32","author":"Chuang","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1126\/science.1139517","article-title":"CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disease","volume":"315","author":"Jung","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1471-4159.2009.06302.x","article-title":"The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies","volume":"110","author":"Bauer","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00018-003-3013-z","article-title":"Polyglutamine diseases: a transcription disorder?","volume":"60","author":"Okazawa","year":"2003","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.7.2.201","article-title":"Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases","volume":"7","author":"Steffan","year":"2003","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","article-title":"Histone deacetylase inhibitors as therapeutics for polyglutamine disorders","volume":"7","author":"Butler","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1755-5949.2010.00184.x","article-title":"Targeting histone deacetylases for the treatment of Huntington's disease","volume":"16","author":"Gray","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib13","first-page":"52","article-title":"Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders","volume":"27","author":"Jiang","year":"2010","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.1087503","article-title":"Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein","volume":"17","author":"Taylor","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","article-title":"HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3","volume":"41","author":"Chou","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.mp.4001518","article-title":"Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers","volume":"9","author":"Gould","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib19","doi-asserted-by":"crossref","first-page":"e54792","DOI":"10.1371\/journal.pone.0054792","article-title":"Sodium valproate alleviates neurodegeneration in SCA3\/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4","volume":"8","author":"Yi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib20","first-page":"1","article-title":"Clinical features and classification of inherited ataxias","volume":"61","author":"Harding","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pneurobio.2007.01.005","article-title":"Mind does really matter: evidence from neuroimaging studies of emotional self-regulation, psychotherapy, and placebo effect","volume":"81","author":"Beauregard","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000097757","article-title":"A\u00a0placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease","volume":"23","author":"Herrmann","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/156720505774932205","article-title":"A\u00a0randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease","volume":"2","author":"Profenno","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.21620","article-title":"Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis","volume":"66","author":"Piepers","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib26","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib27","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib28","first-page":"820","article-title":"Post-insult valproate treatment potentially improved functional recovery in patients with acute middle cerebral artery infarction","volume":"6","author":"Lee","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.03.005_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00210-013-0853-4","article-title":"Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties","volume":"386","author":"Ximenes","year":"2013","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.parkreldis.2016.03.005_bib32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1167\/iovs.09-3903","article-title":"Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells","volume":"51","author":"Biermann","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016300591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016300591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T15:53:49Z","timestamp":1589644429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016300591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":32,"alternative-id":["S1353802016300591"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.03.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of valproic acid treatment in SCA3\/MJD patients","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}